Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

* Reported total revenue of $13.9 million in the second quarter of 2026 primarily driven by 28% growth in the Surgical Aesthetics segment * Successful limited launch of the power liposuction handpiece for the AYON platform to key surgeons in critical geographies; initial commercial shipments in June 2026 * Reaffirmed total revenue guidance for FY2026 of $59.0 million to $60.0 million * Management to host a conference call today at 4:30 p.m. ET CLEARWATER, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the leader in surgical aesthetics marketed and sold as Renuvion(®) and the AYON Body Contouring System(™) (AYON), today reported financial results for its second quarter ended June 30, 2026.

Recent Financial and Operating Highlights: * Reported total revenue of $13.9 million in the second quarter of 2026, compared with $11.4 million in the same period last year. * Surgical Aesthetics revenue increased to $12.4 million in the second quarter of 2026, compared with $9.7 million in the second quarter of 2025, which was the result of sales of AYON, Renuvion generators internationally, and single-use handpieces domestically. * OEM revenue was approximately $1.5 million in the second quarter of 2026, representing a decrease of 12% from the same period last year.